Hemorrhoids Market

 Market Overview:

The 7 major hemorrhoids markets reached a value of US$ 1.32 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.45 Billion by 2034, exhibiting a growth rate (CAGR) of 5.7% during 2024-2034.

The hemorrhoids market has been comprehensively analyzed in IMARC's new report titled "Hemorrhoids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hemorrhoids, also known as piles, are swollen and inflamed veins in the rectum and anus that result in discomfort and bleeding. These vascular structures, crucial for controlling bowel movements, can become problematic when they are subjected to increased pressure. Common symptoms include rectal pain, itching, and bleeding during bowel movements. Individuals suffering from this ailment may also experience a lump or swelling around the anal region, contributing to a sense of discomfort. Diagnosing hemorrhoids typically involves a comprehensive examination by a healthcare professional. Doctors may conduct a physical examination, assessing the anal area for signs of swelling, inflammation, or external lumps. In some cases, internal hemorrhoids may require further evaluation through procedures like anoscopy, sigmoidoscopy, or colonoscopy to get a clearer view of the affected area. Identifying the severity and type of hemorrhoids is crucial for determining an appropriate treatment plan for the patient.

The escalating prevalence of somatic mutations within the GNAQ gene, triggering the excessive growth of blood vessels in specific body regions, particularly the anorectal area, is primarily driving the hemorrhoids market. In addition to this, the inflating utilization of effective interventions, including topical creams, fiber supplements, and minimally invasive procedures like rubber band ligation or sclerotherapy, to manage symptoms and alleviate discomfort is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications, such as dietary adjustments and increased physical activity aimed at preventing and managing hemorrhoids, is further bolstering the market growth. Apart from this, the rising usage of advanced surgical interventions like hemorrhoidectomy or stapled hemorrhoidopexy as viable options for severe cases is acting as another significant growth-inducing factor. Additionally, the emerging popularity of preventive measures and patient education, that help in emphasizing the importance of a healthy lifestyle and early intervention, is also augmenting the market growth. Furthermore, the increasing demand for emerging therapeutic modalities, including novel drug formulations and targeted therapies, which hold promise for addressing the underlying causes of the disease, is expected to drive the hemorrhoids market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hemorrhoids market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hemorrhoids and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hemorrhoids market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hemorrhoids market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hemorrhoids market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current hemorrhoids marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the hemorrhoids market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hemorrhoids market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hemorrhoids market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of hemorrhoids across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hemorrhoids by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hemorrhoids by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hemorrhoids by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with hemorrhoids across the seven major markets?
• What is the size of the hemorrhoids patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hemorrhoids?
• What will be the growth rate of patients across the seven major markets?
   

Hemorrhoids: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hemorrhoids drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hemorrhoids market?
• What are the key regulatory events related to the hemorrhoids market?
• What is the structure of clinical trial landscape by status related to the hemorrhoids market?
• What is the structure of clinical trial landscape by phase related to the hemorrhoids market?
• What is the structure of clinical trial landscape by route of administration related to the hemorrhoids market?